Pain Therapeutics chides FDA for 'shambolic' abuse-deterrent regulations

Pain Therapeutics Inc. (NASDAQ:PTIE) said FDA's regulatory procedures for gaining approval of abuse deterrent products lacks predictive pathways for development and commercialization. The company's comments follow a Jan. 31 meeting with FDA to discuss an NDA seeking approval of pain therapy Remoxy ER oxycodone extended

Read the full 457 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE